Dr. Yu's Publications:
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group. Anti-GD2 Antibody with GM-CSF, interleukin-2 and Isotretinoin for Neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34
Matthay KK, Rani EG. Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10) 2740-53, 2012 PMID: 22589483
Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, Lai AC, Yu JC, Yu AL. (2013) The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res. 15(3):R39. PMID: 23663564
Yu AL, Gilman AL, Ozkaynak MF, Fevzi, M, Sondel, PM, London WB, Cretella, S, Diccianni, M, Cohn SL, Maris JM, Smith, M, Park, Julie on befalf of Children's Oncology Group. Update of Outcome for High-Risk Neuroblastoma Treated on a Randomized Trial of chimeric anti-GD2 antibody (ch14.18) + GM-CSF / IL2 immunotherapy in 1st response: A Children's Oncology Group Study. Advances in Neuroblastoma Research, 2014.
Mody R., Naranjo A., Van Ryn C., Yu AL., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Sondel P.M., Maris J.M., Park J.R., Bagatell R*. Randomised phase II trial of Irinotecan/Temozolomide (I/T) with Temsirolimus (TEM) or Dinutuximab (DIN) in children with refractory or relapsed neuroblastoma: a report from the COG. The Lancet Oncology 2017, 18:946-957
Ozkaynak M., London W., Naranjo A., Diccianni M., Tenney S., Smith M., Messer K., Gilman A., Seeger R., Reynolds C.P., Smith M. Shulkin B., Parisi M., Maris J., Park J., Sondel P., and Yu AL. A Comprehensive Safety Trial of Ch14.18 with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: COG ANBL0931. Front Immunol. 2018 18;9:1355.
Mody R., Yu A.L., Naranjo A., Zhang F.F., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Hank J.A., Felder M., Birstler J., Sondel P.M., Asgharzadeh S., Glade-Bender J., Katzenstein H., Maris J.M., Park J.R., Bagatell R. Irinotecan, Temozolomide, and Dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. Journal of Clinical Oncology 2020, 38:2160-9.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189.
Dr. Diccianni's Publications:
Lo, TCT, Barnhill, LM, Kim, Y, Nakae, EA, Yu, AL, Diccianni, MB. Inactivation of SHIP1 in T- cell Acute Lymphoblastic Leukemia due to Mutation and Extensive Alternative Splicing. Leuk Res. 2009, Nov;33(11):1562-6; PMID: 19473701
Williams RT, Barnhill LM, Kuo HH, Lin WD, Batova A, Yu AL, Diccianni MB. Chimeras of p14ARF and p16: Functional Hybrids with the Ability to Arrest Growth. PLoS One. 2014, 9(2):e88219. PMID: 24505435
Barnhill, LM, Williams, RT, Cohen, O, Kim, Y, Batova, A, Mielke, JA, Messer, K, Pu, M, Bao, L, Yu, AL, Diccianni, MB. High expression of CAI2, a 9p21-embedded long non-coding RNA, contributes to advanced stage neuroblastoma. Can Res 2014, 74(14):3753-632014. PMID: 25028366
Mody R., Naranjo A., Van Ryn C., Yu AL., London W.B., Shulkin B.L., Parisi M.T., Servaes S., Diccianni M.B., Sondel P.M., Maris J.M., Park J.R., Bagatell R.* Irinotecan-temozolomide with temsirolimus or Dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomized, phase 2 trial. Lancet Oncology 2017, 18(7): 946-57.
Ozkaynak M., London W., Naranjo A., Diccianni M., Tenney S., Smith M., Messer K., Gilman A., Seeger R., Reynolds C.P., Smith M. Shulkin B., Parisi M., Maris J., Park J., Sondel P., and Yu AL. A Comprehensive Safety Trial of Ch14.18 with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: COG ANBL0931. Front Immunol. 2018, 18;9:1355.
Diccianni MB, Kempińska K, Gangoti JA, Yu AL, Sorkin LS. Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO. PLoS One. 2020, Jul 22;15(7):e0236115. doi: 10.1371/journal.pone.0236115. eCollection 2020.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021, Apr 15;27(8):2179-2189.
Dr. Batova's Publications:
Batova A, Altomare D, Chantarasriwong O, Ohlsen KL, Creek KE, Lin YC, Messersmith A, Yu AL, Yu J, Theodorakis EA.The synthetic caged garcinia xanthone cluvenone induces cell stress and apoptosis and has immune modulatory activity. Mol Cancer Ther. 9: 2869-78, 2010.
Williams, R.T., Yu, A.L., Diccianni, M.B., Theodorakis, E.A., Batova, A. Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. Journal of Experimental and Clinical Cancer Research. 32:57, 2013.
Batova A, Altomare D, Creek KE, Naviaux RK, Wang L, Li K, Green E, Williams R, Naviaux JC, Diccianni M, Yu AL. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. PLoS One. 2017 Mar 15;12(3):e0172632